Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tryptamine Therapeutics ( (AU:ENP) ) just unveiled an update.
Entropy Neurodynamics has issued 762,195 fully paid ordinary shares to directors in lieu of cash fees, following prior shareholder approval at its November 2025 annual general meeting. The move marginally dilutes existing shareholders but preserves cash, and the company has confirmed ongoing compliance with its financial reporting and continuous disclosure obligations, stating there is no excluded information that would affect secondary trading of these new shares.
The board-authorised notice, released under section 708A(5)(e) of the Corporations Act, ensures the new shares can be freely traded on the secondary market without a separate disclosure document. This step signals that governance and regulatory requirements remain on track, providing reassurance to investors about transparency and the integrity of the company’s capital management practices.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited (ASX: ENP) is an Australia-based company listed on the ASX, operating in the neurotechnology and therapeutics sector. The company focuses on developing and commercialising solutions related to neurological conditions, positioning itself within the broader life sciences and biotech investment market.
Average Trading Volume: 2,293,449
Technical Sentiment Signal: Sell
Current Market Cap: A$47.3M
For detailed information about ENP stock, go to TipRanks’ Stock Analysis page.